JP2020517635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517635A5 JP2020517635A5 JP2019556860A JP2019556860A JP2020517635A5 JP 2020517635 A5 JP2020517635 A5 JP 2020517635A5 JP 2019556860 A JP2019556860 A JP 2019556860A JP 2019556860 A JP2019556860 A JP 2019556860A JP 2020517635 A5 JP2020517635 A5 JP 2020517635A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- cell
- combination
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023054969A JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488181P | 2017-04-21 | 2017-04-21 | |
| US62/488,181 | 2017-04-21 | ||
| PCT/US2018/028577 WO2018195427A2 (en) | 2017-04-21 | 2018-04-20 | Oncolytic virotherapy and immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023054969A Division JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517635A JP2020517635A (ja) | 2020-06-18 |
| JP2020517635A5 true JP2020517635A5 (enExample) | 2021-05-20 |
| JP7260173B2 JP7260173B2 (ja) | 2023-04-18 |
Family
ID=62196688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556860A Active JP7260173B2 (ja) | 2017-04-21 | 2018-04-20 | 腫瘍溶解性ウイルス療法および免疫療法 |
| JP2023054969A Active JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023054969A Active JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11896634B2 (enExample) |
| EP (1) | EP3612202A2 (enExample) |
| JP (2) | JP7260173B2 (enExample) |
| KR (2) | KR102830905B1 (enExample) |
| CN (1) | CN110785180B (enExample) |
| AU (2) | AU2018254566B2 (enExample) |
| CA (1) | CA3060573A1 (enExample) |
| NZ (1) | NZ758626A (enExample) |
| SG (1) | SG11201909749PA (enExample) |
| TW (1) | TWI799411B (enExample) |
| WO (1) | WO2018195427A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
| EP3198009B1 (en) | 2014-09-24 | 2021-09-08 | Salk Institute for Biological Studies | Oncolytic tumor viruses and methods of use |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| EP3390428B1 (en) | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| JP7794421B2 (ja) | 2016-12-12 | 2026-01-06 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍を標的にする合成アデノウイルスおよびその使用 |
| AU2018254566B2 (en) * | 2017-04-21 | 2025-02-13 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| SG10201801219VA (en) * | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| TW202011977A (zh) * | 2018-04-20 | 2020-04-01 | 貝勒醫學院 | 溶瘤病毒療法及免疫療法 |
| US11413315B2 (en) * | 2018-04-29 | 2022-08-16 | City Of Hope | Neural stem cell-mediated cancer treatment |
| TWI856035B (zh) * | 2018-10-25 | 2024-09-21 | 貝勒醫學院 | 溶瘤病毒療法及免疫療法 |
| KR20210134321A (ko) * | 2019-02-01 | 2021-11-09 | 노바록 바이오테라퓨틱스 리미티드 | 항-클라우딘 18 항체 및 이의 이용 방법 |
| CN111743923B (zh) * | 2019-03-27 | 2024-11-08 | 北京康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 |
| IL292788B2 (en) * | 2019-04-29 | 2023-12-01 | Mayo Found Medical Education & Res | Multivalent pd-l1 binding compounds for treating cancer |
| US20220387530A1 (en) * | 2019-11-07 | 2022-12-08 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| CN111632146B (zh) * | 2020-05-29 | 2021-09-28 | 中山大学 | Oat抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| CN111676245B (zh) * | 2020-06-24 | 2022-09-13 | 武汉波睿达生物科技有限公司 | 一种含有HSV-1型溶瘤病毒的NFAT-Cre-CAR-T细胞及其应用 |
| WO2022007804A1 (zh) * | 2020-07-07 | 2022-01-13 | 深圳市菲鹏生物治疗股份有限公司 | T淋巴细胞及其应用 |
| CN113425856B (zh) * | 2021-07-07 | 2022-01-04 | 浙江康佰裕生物科技有限公司 | 一种含有基因修饰的溶瘤病毒的药物组合物及其在治疗癌症的用途 |
| WO2023076469A1 (en) * | 2021-10-29 | 2023-05-04 | Unm Rainforest Innovations | Oncolytic virotherapy compositions and methods |
| CN114032323B (zh) * | 2021-11-17 | 2023-08-08 | 云南省烟草农业科学研究院 | 一种与雪茄烟抗黑胫病基因紧密连锁的共显性ssr标记及其应用 |
| WO2024042231A1 (en) * | 2022-08-26 | 2024-02-29 | Universite De Namur | Adenovirus-based adjuvants for cancer treatment |
| CN116196402A (zh) * | 2022-11-01 | 2023-06-02 | 山东大学齐鲁医院 | 表达双特异性抗体的溶瘤腺病毒联合cart在肿瘤治疗中的应用 |
| WO2024229083A1 (en) * | 2023-05-03 | 2024-11-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN118930652B (zh) * | 2024-07-29 | 2025-03-11 | 北京肿瘤医院(北京大学肿瘤医院) | 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0931830B1 (en) | 1993-02-16 | 2001-03-07 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and phophylaxis of neoplasia |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
| US6730507B1 (en) | 1993-06-24 | 2004-05-04 | Merck & Co., Inc. | Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration |
| US7045347B2 (en) | 1993-06-24 | 2006-05-16 | Advec, Inc. | Helper dependent adenovirus vectors based on integrase family site-specific recombinases |
| US6080569A (en) | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
| AU4592697A (en) | 1996-09-24 | 1998-04-17 | Dana-Farber Cancer Institute | Method of targeting malignant cells using an e2f responsive promoter |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| US20060275262A1 (en) | 2001-07-26 | 2006-12-07 | Mathis James M | Conditionally replicating viruses and methods for cancer virotherapy |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| KR100523028B1 (ko) | 2003-02-27 | 2005-10-20 | 윤채옥 | 개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터 |
| HUE031689T2 (en) | 2008-12-22 | 2017-07-28 | Targovax Oy | Oncolytic adenoviral vectors and related procedures and applications |
| RU2013118724A (ru) | 2010-09-24 | 2014-10-27 | Онкос Терапьютикс Ой | Онколитические аденовирусные векторы и связанные с ними способы и применения |
| WO2012038606A1 (en) | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| PL2623604T3 (pl) | 2012-02-02 | 2015-07-31 | Baylor College Medicine | Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów |
| DK2948553T3 (da) | 2013-01-25 | 2020-06-29 | Baylor College Medicine | Hjælper-afhængigt afgivelses- og ekspressionssystem til adenoviral genterapi |
| KR102089121B1 (ko) * | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| CN106831987B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
| CN106831986B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
| AU2018254566B2 (en) | 2017-04-21 | 2025-02-13 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
-
2018
- 2018-04-20 AU AU2018254566A patent/AU2018254566B2/en active Active
- 2018-04-20 SG SG11201909749P patent/SG11201909749PA/en unknown
- 2018-04-20 TW TW107113504A patent/TWI799411B/zh active
- 2018-04-20 CN CN201880042149.2A patent/CN110785180B/zh active Active
- 2018-04-20 CA CA3060573A patent/CA3060573A1/en active Pending
- 2018-04-20 JP JP2019556860A patent/JP7260173B2/ja active Active
- 2018-04-20 US US16/607,066 patent/US11896634B2/en active Active
- 2018-04-20 KR KR1020197033577A patent/KR102830905B1/ko active Active
- 2018-04-20 EP EP18725690.4A patent/EP3612202A2/en active Pending
- 2018-04-20 WO PCT/US2018/028577 patent/WO2018195427A2/en not_active Ceased
- 2018-04-20 NZ NZ758626A patent/NZ758626A/en unknown
- 2018-04-20 KR KR1020247016403A patent/KR20240093758A/ko active Pending
-
2019
- 2019-06-03 US US16/430,347 patent/US10716818B2/en active Active
-
2023
- 2023-03-30 JP JP2023054969A patent/JP7620994B2/ja active Active
-
2025
- 2025-05-09 AU AU2025203355A patent/AU2025203355A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517635A5 (enExample) | ||
| JP2013107899A5 (enExample) | ||
| JP2018139586A5 (enExample) | ||
| JP2008056679A5 (enExample) | ||
| JP2011521662A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| JP2019531728A5 (enExample) | ||
| JP2015096070A5 (enExample) | ||
| JP2017513502A5 (enExample) | ||
| CN102633883A (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2020531032A5 (enExample) | ||
| JP2015509707A5 (enExample) | ||
| JP2016505635A5 (enExample) | ||
| CN106029889A (zh) | 表达免疫细胞刺激受体激动剂的腺病毒 | |
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2010519931A5 (enExample) | ||
| Yumul et al. | Epithelial junction opener improves oncolytic adenovirus therapy in mouse tumor models | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2015525230A5 (enExample) | ||
| JP2016513471A5 (enExample) | ||
| JP2019519529A5 (enExample) | ||
| JP2015532265A5 (enExample) | ||
| JP2017507943A5 (enExample) | ||
| JP2019531293A5 (enExample) |